Nexthera Capital LP Purchases 92301 Shares of Shire PLC (NASDAQ:SHPG)

Sean Reid
March 30, 2018

The firm has a market cap of $38,374.66, a price-to-earnings ratio of 9.17, a price-to-earnings-growth ratio of 0.73 and a beta of 1.44. This was shown in a research note on Wednesday, 28 March.

Bedell Frazier Investment Counseling Llc decreased Shire Plc (SHPG) stake by 32.16% reported in 2017Q4 SEC filing. The stock of, Inc. The institutional investor held 8,134 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.26M, down from 40,396 at the end of the previous reported quarter. (NYSE:XYL). Arizona State Retirement Systems stated it has 0.08% of its portfolio in Xylem Inc. The stock increased 1.37% or $1.76 during the last trading session, reaching $130.3. It has outperformed by 81.32% the S&P500.

Japan's largest pharma group Takeda is considering a takeover bid for Irish rare disease specialist Shire.

"There can be no certainty that any firm offer for the company will be made nor as to the terms on which any firm offer might be made". It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. The company has a market capitalization of $29,140.00 and a PE ratio of 2,413.79. The Company's marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company's stock. Therefore 77% are positive.

Jefferies analyst Peter Welford, who rates Shire a "buy", said he could "see the potential strategic rationale for the deal" but flagged concerns over Takeda's relative size.

Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Wednesday, February 14th. Goldman Sachs restated a conviction-buy rating and issued a GBX 6,000 ($82.90) target price on shares of Shire in a research report on Friday, November 24th. The rating was maintained by Cantor Fitzgerald on Thursday, August 18 with "Buy". The stock now has a consensus rating of Buy and a consensus price target of $204.00. The company was maintained on Tuesday, November 28 by Jefferies. Exane downgraded the shares of SHPG in report on Thursday, August 6 to "Outperform" rating. On Thursday, October 15 the stock rating was maintained by AlphaValue with "Buy". The stock decreased 3.43% or $51.34 during the last trading session, reaching $1445.71. About 7.00 million shares traded or 444.38% up from the average. After a recent check, Shire plc, (NASDAQ: SHPG)'s last month price volatility comes out to be 2.01% which for the week stands at 1.43%. It has underperformed by 12.01% the S&P500. Therefore 15% are positive. Shire plc (ADR) had 75 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned "Buy" rating on Friday, September 1 by Stifel Nicolaus. They use historic price data to observe stock price patterns to predict the direction of that price going forward. Sterne Agee CRT has "Neutral" rating and $80 target. The company was upgraded on Wednesday, June 21 by Morgan Stanley.

In January, Takeda agreed to buy Belgian biotech group TiGenix NV for 520 million euros, funding the deal with cash on hand, and a year ago, it bought USA cancer drug specialist Ariad for $5.2 billion. RBC Capital Markets maintained the stock with "Buy" rating in Monday, February 5 report.

Investors sentiment increased to 1.08 in 2017 Q4. Volumes indicate how many shares are bought and sold over a given period of time. 168 funds opened positions while 667 raised stakes. Moreover, M&T Savings Bank Corporation has 0.01% invested in Xylem Inc. (NASDAQ:VRNS) for 5,661 shares. Parkside Bankshares Tru holds 656 shares. The company has a quick ratio of 0.55, a current ratio of 0.97 and a debt-to-equity ratio of 0.46. Woodmont Investment Counsel Limited Liability holds 0.12% or 394 shares.

Analysts noted that, even before news of the potential takeover broke, the market cap of Takeda was only slightly above that of Shire. Quantitative Systematic Strategies Lc reported 5,498 shares.

Other reports by

Discuss This Article